As part of an academic medical center, the Division of Cardiology within the Department of Medicine at Northwestern University Feinberg School of Medicine (Feinberg) aims to improve the human health through scientific research.
About Clinical Trials
Clinical trials test or study drugs, surgical procedures, medical devices, or interventions with human subjects. They look to determine their safety and effectiveness in relation to treating specific diseases. Clinical trials are part of clinical research and are at the heart of all medical advances.
Division of Cardiology, Department of Medicine
The following searchable list includes all the Division of Cardiology, Department of Medicine clinical trials currently looking for participants.
Please feel free to contact us with inquiries about any of our ongoing research.
Non-invasive Detection of Right Ventricular Interstitial Fibrosis using MRI in Patients with Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction
This study seeks to explore the structural alterations in the right ventricle (RV) of patients with heart failure with preserved ej…
This study seeks to explore the structural alterations in the right ventricle (RV) of patients with heart failure with preserved ejection fraction (HFpEF) by employing cardiac MRI-derived T1 mapping, an indicator of the degree of diffuse fibrosis, that may allow us to answer the following research questions: 1) Does T1 mapping accurately detect diffuse RV fibrosis?; 2) Do pulmonary hypertension (PH) HFpEF patients have increased RV fibrosis compared to controls and/or HFpEF patients without PH?; 3) Does the amount of RV fibrosis correlate with the degree of RV dysfunction?; 4) Does the degree of RV fibrosis vary between various etiologies of PH? Given NMHC's unique and robust HFpEF program and strength in cardiovascular MR research, Northwestern is uniquely suited for this endeavor. The ultimate goal is to provide mechanistic insight into these conditions so that effective, targeted therapies can be developed.
For more information on this study please contact us:1-855-NU-STUDY
AdreView™ Myocardial Imaging for Risk Evaluation – A multicentre trial to guide ICD implantation in NYHA class II & III heart failure patients with 30%≤LVEF≤35%.
Currently, only about half of all patients with Heart Failure who meet the criteria for an ICD device actually receive one. Also, s…
Currently, only about half of all patients with Heart Failure who meet the criteria for an ICD device actually receive one. Also, some patients who receive an ICD device do not benefit from the device but rather incur the increased risks that are associated with the introduction of devices into the body. The purpose of this study is study is to evaluate if an AdreView™ heart function scan can help identify HF patients who may be more or less likely to benefit from having an ICD device implanted. Some research suggests that an ICD device may not be suitable for all patients with mild to moderate HF and a heart blood-pumping efficiency that is between 30% and 35% (ejection fraction 30-35%). An AdreView™ heart function scan could be used to identify people who have a high or low risk of a fatal event in the next 1 to 2 years. This additional information may make it possible to take a more accurate decision about who would and who would not benefit from an ICD device implantation. We expect that participants in the study will be involved for approximately 2¾ to 3 years and will need to come to clinic for study visits 8-9 times, depending upon if an ICD device is received as part of the patient's standard care or not. All participants involved in this study will receive an AdreView™ heart function scan. This heart function scan uses a radioactive imaging drug, AdreView™, which is already approved in the U.S. and Canada for diagnosing other diseases (e.g., cancers). AdreView™ is already approved in the United States by the U.S. Food and Drug Administration (FDA) for imaging the hearts of people with HF. We expect up to 25 people here will be in this research study out of approximately 2200 people in the entire study internationally.
• ≥18 years of age
• Females pre-menarchal, surgically sterile, postmenopausal, or negative pregnancy test
• Heart failure NYHA classes II or III for symptoms, ischemic or non-ischemic heart disease, eligible for ICD implantation
• Non-ischemic dilated cardiomyopathy or ischemic heart disease of at least 3 months duration
• 30% ≤ LVEF ≤ 35%
• Clinically stable HF (i.e., no significant changes in medication, no worsening of symptoms, no unscheduled visits to the doctor’s office) for the past 30 days
• Reasonable expectation of meaningful survival for at least 1 year
• Existing ICD or indication of ICD implantation for secondary prevention of SCD
• Hospitalized for HF or for acute coronary syndrome in the previous 40 days
• Cardiac resynchronization therapy (CRT) is planned or indicated
• Other indication for placement of device (sustained ventricular tachycardia, resuscitated sudden death, need for atrioventricular pacing)
• NYHA class I or class IV symptoms
• ACC-AHA class III or class IV (unstable) angina
• Chronic renal insufficiency (serum creatinine ≥ 3 mg/dl or 265.2 μmol/L)
• Known or suspected hypersensitivity/allergy to Iobenguane or to any of the excipients in AdreView™ (Iobenguane I123 Injection)
• Pregnant or plans to become pregnant within 2 weeks after AdreView™ administration.
• Use of medication that could interfere with the test: e.g. amitriptyline or derivatives, imipramine or derivatives, other antidepressants or drugs which inhibit the norepinephrine transporter, antihypertensives that deplete norepinephrine stores or inhibit reuptake, sympathomimetic amines or cocaine
• Medical condition that could interfere with the AdreView™ test (e.g. left ventricular assist device or prior heart transplant)
• Participation in a drug or device study within 30 days
• Serious non-cardiac medical condition associated with significant elevation of plasma catecholamines, including pheochromocytoma
• Parkinson’s Disease or Multiple System Atrophy.
• Participation in a research study using ionizing radiation in the previous 12 months